Sugi Predict

Sugi Predict / Compounds / SCHEMBL19486351

SCHEMBL19486351

SCHEMBL19486351

CC(C)N1CCN(c2ccc(-c3cc4c(N5CCN(C(=O)[C@H]6CC[C@H](O)CC6)CC5)ccnn4c3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.41
▸ RET P07949 3/20 0.41
▸ TDP1 Q9NUW8 2/20 0.40
▸ RUVBL1 Q9Y265 1/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 4/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ BMPR1B O00238 1/20 0.37
▸ BMPR1A P36894 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ ACVRL1 P37023 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ MCHR1 Q99705 1/20 0.37
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19481807 0.96 HRH3 (0.43) HRH3TDP1RUVBL1MMP2MMP13
SCHEMBL19481980 0.91 RET (0.40) RETTDP1RUVBL1MMP2MMP13
SCHEMBL19481975 0.90 RET (0.39) HRH3RETTDP1RUVBL1MMP2
SCHEMBL19486349 0.90 RET (0.39) HRH3RETTDP1RUVBL1MMP2
SCHEMBL19490793 0.89 HRH3 (0.38) HRH3RETRUVBL1MMP2MMP13
SCHEMBL19481958 0.88 KMT2A (0.41) RETTDP1RUVBL1ALDH1A1MAPT
SCHEMBL19481784 0.88 TLR9 (0.41) HRH3RETALDH1A1MAPTTSHR
SCHEMBL19481957 0.87 BMPR1B (0.45) HRH3RETALDH1A1MAPTBMPR1B
SCHEMBL19481959 0.87 BMPR1B (0.45) HRH3RETALDH1A1MAPTBMPR1B
SCHEMBL19481848 0.87 ITGB3 (0.39) RETTDP1RUVBL1MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 — — US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 — — US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 — — US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 — — US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 HRH3 2428/4885RET 50/4885TDP1 2048/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 HRH3 2428/4885RET 50/4885TDP1 2048/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 HRH3 2428/4885RET 50/4885TDP1 2048/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 HRH3 2988/4885RET 56/4885TDP1 2701/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 HRH3 2428/4885RET 50/4885TDP1 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.